Ra Medical Systems Inc.
05/09/2022 | Press release | Distributed by Public on 05/09/2022 04:52
Ra Medical Systems to Report First Quarter 2022 Financial Results on May 16, 2022
Ra Medical Systems to Report First Quarter 2022 Financial Results on May 16, 2022
Download as PDFMay 09, 2022
CARLSBAD, Calif.--(BUSINESS WIRE)-- Ra Medical Systems, Inc. (NYSE American: RMED) announces that it will report financial results for the three months ended March 31, 2022 after market close on Monday, May 16. Ra Medical management will hold an investment community conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss financial results and provide a company update.
|
Pre-Registration |
Participants can pre-register for the conference call here: |
||
|
Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. |
|||
|
Live Call: |
Those who choose not to pre-register can access the live conference by dialing: |
||
|
U.S. |
866-777-2509 |
||
|
International |
412-317-5413 |
||
|
Request to join the Ra Medical Systems conference call |
|||
|
Live Webcast: |
|||
|
The webcast will be archived for 30 days. |
|||
|
Replay: |
U.S. |
877-344-7529 |
|
|
Canada |
855-669-9658 |
||
|
International |
412-317-0088 |
||
|
Passcode |
6866135 |
||
|
The replay will be available for 48 hours |
About Ra Medical Systems
Ra Medical Systems manufactures the DABRA excimer laser and catheters for the treatment of certain vascular diseases. DABRA has been cleared by the FDA for crossing chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease and has an intended use for ablating a channel in occlusive peripheral vascular disease. In addition, DABRA has been granted CE mark clearance for the endovascular treatment of infrainguinal arteries via atherectomy and for crossing total occlusions. DABRA excimer lasers and catheters are manufactured in a 32,000-square-foot facility located in Carlsbad, California. The vertically integrated facility is ISO 13485 certified and is licensed by the State of California to manufacture sterile, single-use catheters in clean room environments.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005023/en/
At the Company:
Andrew Jackson
Chief Financial Officer, Ra Medical Systems
760-496-9540
[email protected]
Investors:
LHA Investor Relations
Jody Cain
310-691-7100
[email protected]
Source: Ra Medical Systems, Inc.
Released May 9, 2022